Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients. Liu ZY, Yan ZY, Li JF, Zhu YM, et al. Int J Hematol 2025;122:295-300.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu ZY, Yan ZY, Li JF, Zhu YM, et al. Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients. Int J Hematol 2025;122:295-300.
PMID: 40232601